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Abstract 
Background: Coronary artery disease (CAD) is one of the main causes of death all over the world. Predisposing 
factors comprise some infectious etiologies with systemic effects such as the hepatitis C virus and HBV-infection 
might be related to CAD from chronic inflammation process. The relationships between hepatitis B&C virus 
(HBV&HCV) infections and CAD considered a noticeable health problem. In the present study, we evaluated the 
seropositivity of HCV&HCB in CAD patients from the Iranian population. Materials and Methods: We conducted 
a cohort study including 192 CAD subjects. To identify HCV&HCB -infected subjects, a serologic examination 
comprising Hepatitis B surface antigen (HBsAg) and anti-HCV antibodies (HCV-Ab) tests performed by ELISA 
method. Also, we examined the biochemical blood parameters such as lipid profile, glycemic parameters, and blood 
inflammatory factor (C-reactive protein). Results: We identified a very low percent of HBV-infected cases 
(1.04%). All examined CAD patients indicate the HCV Ab-negative results. The HBV-infected subject had not, 
hyperlipidemia, and diabetes. HBV infection was not related to the increased risk of CAD. Also, CAD risk factors 
were not associated with the prevalence of HBV&HCV. Conclusion: According to the results, HCV&HCB 
infections had very low prevalence in examined subjects and there was not any association between CAD and 
prevalence of HCV&HCB infections.  
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Coronary artery disease (CAD) as the main 
public health issue is related to the high death rate in 
the Iranian population. CAD recognized by the 
existence of atherosclerosis in the epicardial coronary 
arteries. Atherosclerotic plaques, the main 
characteristic of atherosclerosis, gradually led to 
antegrade myocardial blood flow impairment [1]. 
Previous reports indicated that chronic inflammatory 
conditions are related to chronic infection including 
chronic hepatitis C virus (HCV) infection, which 
could be considered as an autonomous risk factor for 
CAD [2-6]. Besides, as chronic inflammation, HBV-
infected subjects might have an elevated susceptibility 
to CAD [2]. Based on the meta-analysis conducted in 
2016, the pooled prevalence of HBV infection among 
the general population in Iran was 2.2% [7]. About 
HCV infection in Iran, reports indicate that there are 
different incidence patterns of HCV in various 
societies and areas of Iran [8].  
HBV-infection might be related to CAD from 
the chronic inflammation process [2]. Also, 
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predisposing factors comprise some infectious 
etiologies such as the hepatitis C virus have a 
systemic effect  [9]. 
A few current types of research have 
confirmed that HCV infection was related to  CAD. 
Although, many previous studies did not endorse this 
correlation a meta-analysis displayed that HCV 
infection is a possible risk factor for CAD [10]. 
Current reports indicated that HCV infection 
is a risk factor for cardiovascular disorder. Overall 
these findings are controversial [11]. On the other 
side, the association between HBV and CAD also are 
questionable [2]. In this study, we evaluate the HBs 
Antigen (HBS Ag) and the presence of anti-HCV 
antibodies (HCV Ab) in the serum of CAD patients 
to find the association of HCV and HBV infection 
with Cardiovascular disease. 
Methods 
A presented cohort study was carried out on 
192 CAD patients with a mean age of 57.43 ±11.078 
years from Urmia Seyedoshohada heart hospital 
during august 2012-December 2013.  The studied 
subjects evaluated for the seropositivity of HBsAg 
and HCV Ab. All the patients underwent physical 
examinations by the cardiologist and their CAD was 
confirmed. CAD was detected by the presence of 
myocardial infarction or congestive heart failure or 
every sign for coronary artery bypass grafting [12] 
and all subjects underwent coronary angiography. 
The patient's characteristic parameters were obtained 
based on National Care information. Subjects, which 
have a history of prior liver illnesses, diabetes, and, 
were omitted from the survey.  
Permission forms were distributed with 
adequate descriptions for patients about research 
protocols and experimental tests.  
After physical examination of each subject, 5 
ml blood samples were drawn which divided into 
serum (without anticoagulation EDTA) and plasma 
(with anticoagulation EDTA) using the 
centrifugation method. Then separated sera & plasma 
were stored at −20°C until use.  
The serum levels of HBS Ag and presence of 
HCV Ab in CAD patients were assessed by enzyme-
linked immunosorbent assay (ELISA) technique.  
HBsAg was tested by the ELISA method 
(DIA. PRO, Milan, Italy) based on the manufacturer's 
protocol. HCV Ab was assessed using an anti-HCV 
antibody ELISA kit (Anti HCV ELISA, DIAsource, 
Belgium) according to the instruction of the kit. 
Dyslipidemia was detected by evaluation of the 
following parameters: plasma total cholesterol level, 
plasma total triglycerides, high-density lipoproteins 
(HDL-c), which were done by spectrophotometry and 
commercially available kits (Pars Azmoon kit, Pars 
Azmoon Inc., Tehran, Iran), and low-density 
lipoproteins (LDL-c), that measured by enzyme 
colorimetric method after omitting HDL-c, VLDL and 
chylomicron lipoproteins (Pars Azmoon kit, Pars 
Azmoon Inc., Tehran, Iran). was considered 
statistically significant. 
Other blood biochemical factors including 
fasting blood sugar (FBS), blood sugar (BS) as 
glycemic parameters, detected by spectrophotometry, 
and commercially available kits (Pars Azmoon kit, 
Pars Azmoon Inc., Tehran, Iran). Also, an 
inflammatory marker of serum levels of C reactive 
protein (CRP) was determined using 
immunoturbidimetric methods with a commercially 
available latex kit (Aniston). 
Statistical analysis. For data analysis, we 
utilized the SPSS software version 21. To measure the 
main value of quantitative variables and frequency 
(percentage %), T-test was applied. For comparison, 
the mean concentrations of each quantitative factors 
and significant difference between patients 
ANOVA/Chi-square test were used. 
 
Results 
           In our experiments, the age range of the CAD 
patients were 29 to 95 years (88 patients (49.7 %) 
were female and 89 (50.3 %) were male). The Mean 
age of the CAD subjects were 57.43 ±11.078 years. 
Data from demographic, characteristics, and 
biochemical parameters, which obtained from blood 







Rostamzadeh et al.          Seroprevalence of Hepatitis B&C in coronary artery disease patients in Urmia… 
 
 Archives of Medical Laboratory Sciences 
20 
Table1. Demographic and biochemical parameters of CAD 
patients. 
(N=192) 
Parameters Mean± Std. Deviation Std. Error Mean 
Age (year) 57.43 ±11.078 .799 
HDL-c (mg/dl) 37.06 ±19.727 1.718 
LDL-c (mg/dl) 47.27 ±51.372 3.883 
TG (mg/dl) 180.37 ±104.265 7.882 
TC (mg/dl) 125.62 ±67.385 7.307 
BS (mg/dl) 123.46 ±101.199 7.739 
FBS (mg/dl) 108.80 ±54.792                            4.582 
Data presented as Mean± Std. Deviation, TC: Total 
cholesterol, TG triglyceride, BS: blood sugar, FBS: fasting 
blood sugar, LDL-c: low-density lipoprotein cholesterol, 
HDL-c: high-density lipoprotein cholesterol 
 
According to our results, there was any HCV 
Ab positive test in the studied population but two 
subjects had a positive HBsAg (1.04%) test. Based 
on the results, HBV infection had a low prevalence in 
patients with CAD. Data from the HBsAg and 
HCVAb tests, which classified as seronegative or 
seropositive were presented in Tables 2 and 3 
respectively. 
 
Table2. HBsAg seroprevalence in CAD patients. 
Percent% frequency HBsAg 
1.04                                     2 seropositive 
98.95                                190 seronegative 
100.0                                192                            total 
 
Table2. HCVAb seroprevalence in CAD patients. 
Percent% frequency HBsAg 
0                                     0 seropositive 
100                                192 seronegative 
100.0                                192                            total 
 
Mean plasma levels of total cholesterol, LDL-
c, HDL-c, FBS, BS, and triglycerides were not any 
significant differences in the HBs Ag positive 
subjects in comparison with HBV-uninfected 
patients(p>0.05). Also, the levels of CRP in HBV 
positive cases have no significant differences versus 
uninfected persons (p<0.05). Regression analysis 
revealed that there was any correlation between 
biochemical parameters and the presence of HBV 
infection in CAD patients. 
Discussion 
          The presented study aimed to evaluate the 
prevalence and the possible predisposing effect for 
Hepatitis B and C viruses among CAD patients 
attending the Urmia University of medical sciences, 
Iran. 
          According to our results, 2 (1.04%) and 0 (0%) 
out of 192 CAD subjects who participated in the study 
had positive tests for hepatitis HBS Ag and HCV Ab 
respectively. None of them had mixed infections of 
hepatitis B and C. Besides, in HBV infected 
individuals, any of the studied risk factors had no 
significant differences compared to uninfected cases. 
        In previous reports, the relationships among 
chronic inflammation and increased risk of 
atherosclerosis have been distinguished. Surveys have 
shown a higher risk of CAD between hepatitis C 
patients versus uninfected individuals [3, 13]. 
Nonetheless, in the presented survey, there was no 
significant correlation between CAD and HBV 
infection. 
        The cause behind the absence of relationships 
may be related to this fact that the inflammatory 
burden of chronic HBV infection is comparatively 
insignificant [2]. Indeed, mean CRP levels among 
HBV-infected patients were not any significant 
differences to HBs Ag-seronegative subjects.   
         In accordance with our findings, previous reports 
indicate that HBV-positive people did not show a 
higher incidence rate of customary risk factors of CAD 
such as diabetes, and hyperlipidemia. Indeed, in this 
study, which carried out in Madani Heart Hospital, 
Tabriz, Iran, researchers reported that the incidence of 
HBsAg positivity inclined to be more in CAD subjects 
versus healthy individuals, but the difference did not 
reach to statistically significant level [14]. 
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           The lack of metabolic disorders might be an 
additional feature for the absence of possible CAD 
risk between these individuals. In another study, 
Ishizaka et al confirmed the HBV infection in the 
carotid arteriosclerosis pathogenesis. Also, they 
indicated that the seropositivity of HBV surface 
antigen might be a risk factor for atherosclerosis [15] 
which are discordance to our results.Arcari et al. [16] 
in their cohort study with the investigation of 582 
subjects, concluded that HCV infection has not any 
relationship with Acute Myocardial Infarction. 
           Another study in 2013, by Miyajima et al. [17] 
indicates that HCV can be related to atherosclerosis. 
           Also, Butt et al (12) showed that patients with 
HCV infection have lower lipid levels than healthy 
control subjects. Also, they concluded that HCV 
infection could be associated with developing 
CAD.Another study shows the positive association 
among HCV seropositivity and the complexity of 
coronary lesions in the light of the SYNTAX score 
[18]. 
           These variations, among our study and other 
mentioned surveys, might be related to the 
particularities in the ways of transmission of HBV 
and HCV, which is related to socio-cultural and 
environmental factors. Furthermore, our findings 
showed a low frequency of hepatitis B infection 
among the CAD population of Urmia city.  
           Although the prevalence of HCV infection 
was reported to be zero in this population, screening 
strategies may be suitable. Also, further examination 
for HCV in the larger population is suggested. This 
low rate of seropositivity would be related to the low 
number of studied individuals in the present survey; 
therefore, evaluating a large sample is recommended. 
           Overall, it is vital to assess the HBV and HCV 
prevalence among CAD subjects as specific health 
policies can be invented and infected CAD 
individuals are counseled and treated.  
 
Conclusion 
           We have concluded that the prevalence of 
HBsAg, HCVAb among CAD was lesser than in the 
general population. The results of the presented study 
may be valuable for counseling and management of 
these patients, and further studies analyzing the risk 
for HBV and HCV transmission in Iranian CAD 
subjects. Higher standards of CAD patient's health and 
well-being increases not only their lives, but it also 
related to the health of their family and community. 
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